CD4 and neoplasm: Based on the quanTIseq analysis, T3 could have had a higher chance of responding to immunotherapy than T1 and T2, in view of higher M1/M2 macrophages, lower frequency of regulatory T cells, detectable percentages of dendritic cells and CD4+ T cells, in addition to a high tumour mutational burden and defective DNA mismatch repair signature [46,48].